Who
Mary Kay Fenton
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Cullinan Therapeutics; Chief Financial Officer, Talaris Therapeutics; Director, Oncorus; Chief Financial Officer, Achillion Pharmaceuticals.
In numbers
- Trades disclosed
- 53
- Buys
- 1
- Sells
- 9
- Bought
- $10K
- Sold
- $1.0M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 18 Dec 2006
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,541 at $8.60 | filing |
| 30 Jun 2026filed 2 Jul 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K1,541 at $8.60 | filing |
| 20 Feb 2026filed 23 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $60K4,398 at $13.62 | filing |
| 20 Feb 2026filed 23 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Sold | $60K4,398 at $13.62 | filing |
| 18 Feb 2026filed 19 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | —68,750 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,500 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,500 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | —68,750 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | $17527 at $6.49 | filing |
| 31 Dec 2025filed 5 Jan 2026 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | $17527 at $6.49 | filing |
| 19 Feb 2025filed 21 Feb 2025 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 19 Feb 2025filed 21 Feb 2025 | CGEM Cullinan TherapeuticsBiotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 29 Apr 2024filed 30 Apr 2024 | CGEM Cullinan Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 3 Jul 2023filed 6 Jul 2023 | Talaris Therapeutics | SEC FORM 4 Code F | $40K12,946 at $3.08 | filing |
| 1 Feb 2023filed 3 Feb 2023 | Talaris Therapeuticsoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 1 Feb 2023filed 3 Feb 2023 | Talaris Therapeuticsoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 10 Sep 2022filed 13 Sep 2022 | Talaris Therapeutics | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 23 Jun 2022filed 24 Jun 2022 | Oncorusoption or derivative | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 1 Feb 2022filed 2 Feb 2022 | Talaris Therapeuticsoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 31 Dec 2021filed 2 Feb 2022 | Talaris Therapeutics | SEC FORM 4 Code A | $13K1,000 at $13.00 | filing |
News
No headline names them, or the companies they trade most, lately.